Background: Tissue factor (TF) is the primary initiator of blood coagulation. In response to tumor necrosis factor (TNF)-α human umbilical vein endothelial cells (HUVECs) express 2 TF isoforms: a soluble alternatively spliced isoform (asHTF) and membrane-bound "full length" (fl)TF. How the differential TF isoform expression is regulated is still unknown. This study compared the impact of PI3K/Akt pathway inhibition on alternative splicing of TF in HUVECs, to the influence of transcriptional regulation by inhibiting nuclear factor κ B (NFκB).
issue factor (TF) is a 47-kD transmembrane cellsurface glycoprotein and the primary initiator of the blood coagulation cascade. [1] [2] [3] [4] Endothelial cells are crucial regulators of vascular wall homeostasis and blood thrombogenicity; 5-7 the inflammatory cytokine tumor necrosis factor (TNF)-α has been shown to induce the expression of 2 TF isoforms: membrane-bound human "full length" TF (flTF), [8] [9] [10] and a soluble alternatively spliced human TF (asHTF). 6, 10, 11 Both TF isoforms circulate in blood. 6, 12 Fully active flTF appears to be the major source of the thrombogenicity of blood in a cancer setting. 13 The function of asHTF is as yet unknown. It has been suggested that asHTF participates in thrombogenesis in vivo, although it is much less procoagulant than flTF in conventional static assays. 6, 12, 14 Alternatively asHTF may be linked to increased cell proliferation and angiogenesis. 15 Alternative splicing of pre-messenger RNA (pre-mRNA) is an important eukaryotic mechanism for regulating gene expression, protein diversity and functional variability. 14, 16 Serine/arginine-rich (SR) proteins are a family of highly conserved factors crucial for constitutive and alternative splicing of pre-mRNA. [16] [17] [18] Several SR protein kinases have been reported to phosphorylate SR proteins, thereby regulating the activity of SR proteins in alternative splicing processes. [17] [18] [19] [20] [21] Protein kinase B (Akt) is one of these SR protein kinases. 18, 22 The phosphatidylinositol 3-kinase (PI3K)/Akt pathway affects SR protein phosphorylation and alternative splicing processes. 23, 24 It is unknown whether SR protein kinases are involved in regulated TF pre-mRNA splicing in endothelial cells. Thus, the present study assessed the impact of the PI3K/Akt pathway on regulating TNF-α-induced TF isoform expression and phosphorylation state of SR proteins in human umbilical vein endothelial cells (HUVECs).
Methods

Cell Culture
Pooled HUVECs were cultured in EC growth medium (containing 5% fetal calf serum) at 37°C in a humidified incubator (5% CO2, 95% air). Cells from passages 2-6 were used. For inhibition experiments, HUVECs were switched to EC basal medium (without fetal calf serum) for 1 h and then pre-treated with 1, 2.5 and 5 μmol/L of the PI3K/Akt pathway inhibitor LY294002 (Calbiochem, Darmstadt, Germany) or 10 μmol/L of the NFκB inhibitor BAY 11-7082 (Calbiochem) for another 1 h. Next, the cells were stimulated with 10 ng/ml TNF-α for 1 h for mRNA analysis or for 5 min for the assessment of the phosphorylation state of SR proteins. Positive controls were stimulated with TNF-α only and negative controls were not treated.
TF Isoform-Specific Real-Time PCR (TaqMan)
Real-time PCR using flTF, asHTF, and GAPDH-specific primers and probes was performed as previously described. 25, 26 Overexpression of SF2/ASF and SRp75 The 1×10 5 HUVECs were transfected with 3 μg of the expression plasmid pCMV6-Entry-SFRS4 or SFRS1 (OriGene Technologies Inc, Rockville, MD, USA) coding for SRp75 or SF2/ASF, respectively. Transfection was performed with a HUVECs Nucleofector ® Kit (Amaxa Biosystems, Cologne, Germany). The overexpression of both SR proteins was monitored by determining mRNA levels after 48 h upon transfection. At 72 h post transfection, cells were stimulated with TNF-α for 1 h, total RNA collected, reverse transcribed, and subjected to real-time PCR analysis.
Determination of TF Activity Measurement of thrombogenicity of stimulated and non-stimulated HUVECs, as well as cells pre-treated with inhibitors, was performed as previously described. 6 
Western Blot
Western blot analysis of samples from cell lysates of inhibited, stimulated and unstimulated HUVECs was performed as previously described. 25 For detection of phosphorylated SR proteins monoclonal antibody mAb1H4 (Invitrogen GmbH, Karlsruhe, Germany) was used. Phosphorylationindependent detection of SRp75, SRp55, and SF2/ASF was done via the monoclonal antibodies mAb16H3 and mAb103 (Invitrogen GmbH).
Quantification of Western Blots
The results of western blot experiments were quantified using Gel-Pro Analyzer™ software version 4.0.00.001 (Media Cybernetics, Bethesda, MD, USA).
Statistical Analysis
All data are expressed as mean ± SEM. Data were analyzed by Student's t-test or 1-way ANOVA as appropriate. A probability value ≤0.05 was regarded as significant. 
Results
Inhibition
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Stimulation of HUVECs with TNF-α tended to result in increased mRNA expression of asHTF, but not flTF 20 min post stimulation (Figures 1A,C) . The mRNA expression of both TF isoforms was significantly increased 60 min post TNF-α stimulation (Figures 1B,D) . Inhibition of the PI3K/ Akt pathway by doses of 1-5 μmol/L of the specific inhibitor LY294002 27 had no significant effect on the TNF-α-induced increase in flTF mRNA at 20 as well as 60 min post TNF-α stimulation (Figures 1A,B) . In contrast to the flTF mRNA expression, the asHTF level was significantly reduced in (Figures 1C,D) .
In contrast to inhibition of the PI3K/Akt pathway, inhibition of NFκB by 10 μmol/L BAY 11-7082 reduced the TNF-α-induced mRNA expression of both TF isoforms (Figures 2A-D) .
Impact of NFκB Inhibition and Inhibition of the PI3K/ Akt Pathway on Thrombogenic Activity of TNF-α-Stimulated HUVECs
NFκB is known to play a role in progressing the inflammatory response in atheroslerosis. 28 To determine the impact of NFκB inhibition or inhibition of the PI3K/Akt pathway on endothelial thrombogenicity, a chromogenic TF activity assay based on generation of factor Xa by TF, was performed (Figure 3) . Stimulation of cells with TNF-α led to a significantly increased TF activity at 5 and 24 h post stimulation compared with non-stimulated controls. Inhibition of the PI3K/Akt pathway with 5 μmol/L of LY294002 had no effect on the TNF-α-induced increase in TF activity. In contrast to inhibition of the PI3K/Akt pathway, inhibition of NFκB reduced the TF activity to baseline level at 5 h as well as 24 h post stimulation with TNF-α.
Inhibition of PI3K/Akt Pathway but Not NFκB Altered the Phosphorylation Pattern of SR Proteins
Western blots with antibodies against phosphorylated SR proteins were performed to assess the phosphorylation state of SR proteins 5 min post TNF-α-stimulation. The SR protein family members, SRp75, SRp55, SC35 and SF2/ASF, were detected in HUVECs (Figure 4A,Left) . We found TNF-α to increase the phosphorylation of these SR proteins (Figures 4B-E) . Treatment of HUVECs with the 5 μmol/L of the PI3K/Akt pathway inhibitor reduced the phosphorylation state of SRp75, SRp55 and SF2/ASF. In contrast, the inhibition of NFκB had no effect on the TNF-α-induced increase in SR protein phosphorylation. By determining the expression of whole SRp75, SRp55 and SF2/ASF via phosphorylation-independent antibodies, we demonstrated that inhibition of neither the PI3K/Akt pathway nor NFκB affected the protein expression level 5 min post TNF-α stimulation (Figure 4A,Right) .
Overexpression of SRp75 Influences Differential TF mRNA Expression
The phosphorylation state of SR proteins regulates their 
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activity in alternative splicing processes. 17, 20 To determine the involvement of the SR proteins mentioned before in the differential TF isoform expression, we exemplarily analyzed the impact of SF2/ASF and SRp75 overexpression on the mRNA expression of flTF and asHTF in HUVECs. As mentioned before, stimulation of HUVECs with TNF-α increased the mRNA expression of both TF isoforms 60 min post stimulation (Figures 5A,B) . Overexpression of SF2/ ASF reduced the mRNA expression of flTF and increased that of asHTF. Overexpression of SRp75 led to reduced flTF expression and had no significant impact on asHTF 60 min post induction with TNF-α. Simultaneous overexpression of both SR proteins in HUVECs also reduced flTF mRNA, but increased asHTF expression. The SF2/ASF expression was approximately 2.5-fold increased ( Figure  5C ) and SRp75 was approximately 3-fold increased 48 h post transfection compared with non-transfected HUVECs ( Figure 5D ).
Discussion
SR protein kinases, such as Akt, control the phosphorylation state and activity of SR proteins, thereby regulating alternative splicing. 18, 19, 22, 29 Our findings demonstrate that the PI3K/Akt pathway is involved in the regulation of the differential TF isoform expression in ECs. We demonstrated the regulatory level of the PI3K/Akt pathway to be distinct from the transcriptional regulation level of NFκB. [30] [31] [32] [33] Inhibition of the PI3K/Akt pathway by the pharmacologic inhibitor, LY294002, reduced the TNF-α-induced mRNA expression of asHTF, but not flTF, in a time-and concentration-dependent manner. In contrast, the inhibition of the transcription factor NFκB diminished the expression of both TF isoforms post stimulation with the pro-inflammatory cytokine TNF-α. Moreover, we found that TNF-α-induced procoagulant activity was not reduced when levels of asHTF mRNA, but not those of flTF, were lowered by inhibition of the PI3K/Akt pathway. In contrast, NFκB inhibition reduced the expression of both TF isoforms, associated with decreased TF activity. This indicates that, compared with flTF, asHTF is likely to be a minor contributor to TNF-α-induced increase in endothelial thrombogenicity. 6, 34, 35 Yu and Rak found that flTF-containing microparticles, rather than asHTF, were the main source of TF activity released from human cancer cells, 13 although in the plasma of healthy individuals, non-microparticle associated TF was shown to be a major source of plasma TF activity. 12 We recently showed that soluble TF is much less procoagulant than microparticle-associated full-length TF released from TNF-α-stimulated HUVECs. 6 Despite its minor role in thrombogenicity, asHTF was assumed to be involved in other cellular processes such as angiogenesis and cell proliferation. 15 Furthermore, we demonstrated in the present study that the inhibition of the PI3K/Akt pathway, but not the NFκB pathway, led to reduced phosphorylation of the SR proteins, SRp75, SRp55 and SF2/ASF, without affecting the expression of these SR proteins 5 min post TNF-α stimulation. In association with these results, we found overexpression of SF2/ASF and SRp75 alone or in combination influenced the mRNA expression pattern of the TF isoforms in TNF-α-induced HUVECs in differing modalities. It has been shown by other groups that the phosphorylation state of SR proteins determines their activity in alternative splicing processes, 17, 20, 36 and the activity of distinct SR proteins determines the expression of different isoforms, as shown for TF and other proteins. 10, 17, 18, 36, 37 Blaustein et al showed Akt to be an SR protein kinase that is involved in regulation of the phosphorylation and the activity of SR proteins such as SF2/ASF and 9G8. 22 Recently, Jiang et al found Akt to regulate induced alternative splicing of protein kinase CβII-pre-mRNA through the phosphorylation of SR proteins. 18 Other groups have demonstrated that the PI3K/ Akt pathway phosphorylates the SR protein SRp40, thereby regulating alternative splicing processes such as splicing of protein kinase CβII. 23, 24 Finally, Tardos et al reported that exon 5 of the human TF gene contains ESE motifs for SR proteins, such as SF2/ASF and SRp55. 36 The binding of SR proteins to these motifs was shown to be essential for the differential TF isoform expression in human monocytic cells. 14 Altogether, the results of the present study point to the PI3K/Akt pathway being, at least in part, involved in the differential TF isoform expression at the mRNA level by regulation of alternative splicing processes, possibly mediated through the phosphorylation state and activity of the SR proteins SRp75, SRp55 and SF2/ASF in TNF-α-induced human ECs. Our results provide new insights into the regulatory network of alternative splicing, especially with respect to the differential TF isoform expression in human ECs. These isoforms are essential for vascular wall homeostasis and blood thrombogenicity. Understanding the regulation of TF mRNA splicing processes may help to develop new strategies for the modulation of vascular wall thrombogenicity.
